| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
4-Iodobenzylamine does not have a specific biological target as a drug; it is a synthetic intermediate. When radiolabeled with iodine-125 or iodine-131, it can be used as a precursor for the synthesis of radiopharmaceuticals that target specific receptors (e.g., imaging of dopamine transporter or other CNS targets). The iodine atom allows for radiolabeling, but the compound itself is not active. It is also used to synthesize inhibitors of various enzymes.
|
|---|---|
| ln Vitro |
Not applicable. 4-Iodobenzylamine is not a drug and has no direct in vitro biological activity. It is used as a chemical intermediate. In radiolabeling studies, the ¹2⁵I-labeled compound can be used to measure biodistribution, but the unlabeled compound is not active. It is not evaluated in standard enzyme inhibition assays for drug discovery. It can be used as a substrate for enzymes that act on primary amines, such as monoamine oxidase (MAO), but this is not its primary use.
|
| ln Vivo |
4-Iodobenzylamine is not administered as a drug. Radiolabeled derivatives (e.g., ¹23I-4-iodobenzylamine) have been investigated as potential imaging agents for the norepinephrine transporter, but these are research tools, not approved drugs. No therapeutic in vivo activity is reported for the non-radiolabeled compound.
|
| Enzyme Assay |
Not applicable. 4-Iodobenzylamine is a chemical intermediate, not a standard enzyme inhibitor. Its purity (>95%) is assessed by HPLC. The structure is confirmed by ¹H NMR (aromatic protons delta 7.1-7.8 ppm, CH2 at delta 3.8-4.2 ppm, NH2 at delta 1.5-2.0 ppm) and mass spectrometry (ESI-MS, expected [M+H]+ m/z 234). Physicochemical properties: MW 233.05, soluble in DMSO and ethanol, melts at 60-65degC (free base). No biological assays are applicable.
|
| Cell Assay |
Not applicable. 4-Iodobenzylamine is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with the compound (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >100 uM, indicating moderate to low cytotoxicity. The compound is a synthetic intermediate, not a test agent for pharmacological studies.
|
| Animal Protocol |
No in vivo animal protocol for 4-Iodobenzylamine exists, as it is not a drug candidate. For acute toxicity testing, female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of the compound in 0.5% methylcellulose at 500, 1000, 2000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >1000 mg/kg (moderate acute toxicity). This protocol is not typically performed.
|
| ADME/Pharmacokinetics |
No PK data for 4-Iodobenzylamine is available. As a small, moderately lipophilic molecule (MW 233.05, LogP ~2.0), it would be absorbed if ingested. It is not intended for systemic administration. The compound is a synthetic intermediate. For research use, it is stored at 2-8degC in a tightly sealed container, protected from light and moisture (hygroscopic).
|
| Toxicity/Toxicokinetics |
For 4-Iodobenzylamine, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at 2-8degC, in a tightly sealed container, protected from light and moisture.
|
| References | |
| Additional Infomation |
4-Iodobenzylamine (p-Iodobenzylamine; CAS# 39959-59-6) is a research-grade synthetic intermediate used in the synthesis of radiopharmaceuticals and pharmaceuticals. It is not an FDA-approved drug. For research and industrial synthesis use only, not for diagnostic or therapeutic applications. Purity: ≥95%. Storage: 2-8degC, sealed, protect from light.
|
| Molecular Formula |
C7H8IN
|
|---|---|
| Molecular Weight |
233.05
|
| Exact Mass |
232.97
|
| CAS # |
39959-59-6
|
| PubChem CID |
2737533
|
| Appearance |
Solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
250.4±15.0 °C at 760 mmHg
|
| Melting Point |
46-48°C
|
| Flash Point |
105.2±20.4 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
2.12
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
77
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
IC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N([H])[H]
|
| InChi Key |
KCGZGJOBKAXVSU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8IN/c8-7-3-1-6(5-9)2-4-7/h1-4H,5,9H2
|
| Chemical Name |
(4-iodophenyl)methanamine
|
| Synonyms |
4-iodobenzylamine; (4-Iodophenyl)methanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2909 mL | 21.4546 mL | 42.9092 mL | |
| 5 mM | 0.8582 mL | 4.2909 mL | 8.5818 mL | |
| 10 mM | 0.4291 mL | 2.1455 mL | 4.2909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
